Spot on, the primary value would be to bundle up with a statin, offer as a single treatment. And yes, should have no probs with patenting that its a new treatment.
Secondary value as a stand alone treatment for those where a statin is ineffective. Could licence out right to use in conjunction with statin, and retain stand alone use development... a few options I suppose.
- Forums
- ASX - By Stock
- NYR
- bull case
bull case, page-117
Featured News
Add NYR (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.7¢ |
Change
-0.002(3.39%) |
Mkt cap ! $10.38M |
Open | High | Low | Value | Volume |
6.3¢ | 6.3¢ | 5.7¢ | $35.22K | 592.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 151330 | 5.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.1¢ | 163950 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 151330 | 0.057 |
3 | 28357 | 0.056 |
2 | 133333 | 0.055 |
2 | 44230 | 0.052 |
2 | 330000 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.061 | 163950 | 1 |
0.064 | 24864 | 1 |
0.065 | 7000 | 1 |
0.069 | 33333 | 1 |
0.070 | 68757 | 4 |
Last trade - 15.59pm 21/06/2024 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online